August 8, 2020 /

In the Pipeline: Combating Fibrosis and Inflammation

Like inflammation, fibrosis is a downstream effect of the lack of dystrophin and occurs as chronic inflammation that prevents muscle repair. Fibrosis is defined as the thickening and scarring of connective tissue, usually as a result of injury. This panel will discuss therapies that aim to reduce fibrosis and inflammation by decreasing the breakdown of mature muscle cells and increasing muscle strength.

FibroGen (Bassem Elmankabadi, MD, Executive Medical supervisor, Global Clinical Development Lead)
Italfarmaco (Paolo Bettica, MD, PhD, CMO)
Capricor (Linda Marban, PhD CEO)
Followed by discussion and Q &A

Join Our Mailing List